FibroBiologics, Inc. (FBLG)

Market Cap	77.64M
Revenue (ttm)	n/a
Net Income (ttm)	-17.78M
Shares Out	34.66M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,886
Open	2.420
Previous Close	2.380
Day's Range	2.163 - 2.507
52-Week Range	1.078 - 46.000
Beta	n/a
Analysts	Strong Buy
Price Target	13.33 (+495.09%)
Earnings Date	Nov 12, 2024

About FBLG

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2024
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: FBLG
• Website: https://www.fibrobiologics.com

Analyst Forecast

According to 3 analysts, the average rating for FBLG stock is "Strong Buy." The 12-month stock price forecast is $13.33, which is an increase of 495.09% from the latest price.

Price Target

$13.33

(495.09% upside)

Analyst Consensus: Strong Buy